ArticleCancer research communications2025
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Ruiliang Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.